The United Kingdom Science Park Association has been supporting science park development since 1984, and now has around 80 science parks, technology parks and innovation-led incubators in membership. Our Members accommodate over 3000 companies who employ around 70,000 highly qualified staff, and turnover in the region of £5.5 bn pa. The Association organises three membership events each year and periodic annual conferences, and supports its membership by ensuring communication between parks is effective, as well as lobbying on behalf of our members and their tenant companies. UKSPA produces a range of information services, such as a monthly e-newsletter and a quarterly magazine.
Extraordinary advances in the life sciences have great potential to improve our quality of life through better medicines and a cleaner environment. Biochemical Engineering provides the foundations for translating such exciting new discoveries into products and processes for improved health and wealth creation. . . At UCL, we offer education for undergraduates, postgraduates and industry professionals in our top-ranked department. Staff are engaged in cutting-edge research, both within the Department and as part of a number of European and international collaborations. In the 2008 Research Assessment Exercise 75% of Academic Staff were rated as World Leading or Internationally Excellent.
We provide an informed entry point into the University for companies, and can help potential partners define their interests, find the appropriate academic expertise, and identify opportunities for collaboration. We support the development of relationships between academics and industry, whether these are major multi-faceted collaborations with global companies or simply finding experts for specific one-off projects.. . RSD can identify opportunities for collaboration between business and academics and negotiate research contracts in exciting interdisciplinary areas, such as computational biology, nanoscience, energy and the environment.. . We work closely with University Departments that offer licences for intellectual property, graduate recruitment and executive education.. . We also coordinate the Corporate Liaison Programme, which enables companies to work with the University of Cambridge.. . Our team of Partnership Development Managers helps companies to navigate the University and build mutually beneficial relationships. For more information on working with the University in specialist industry sectors, email Dr Karen Smith [email protected] or Mr Richard Reschen [email protected]
Essex is the number two university in the UK for the number of Innovate UK-funded projects, and ranks as the leading university in the East of England and London for leveraging R&D grant funding, to collaborate with businesses helping them to drive innovation, improve productivity and ultimately grow.
The university has expertise in the research areas of protein structure and the mechanisms of disease working to establish the link between structure and the physiological function of proteins with research spanning from individual atoms and isolated molecules to cellular biology approaches including pre-clinical models of cancer and immunology. Further fields of expertise are in genetics and computational biology with particular strengths in epigenetics and chromatin structure.
The university has expertise in the research areas of protein structure and the mechanisms of disease working to establish the link between structure and the physiological function of proteins with research spanning from individual atoms and isolated molecules to cellular biology approaches including pre-clinical models of cancer and immunology. Further fields of expertise are in genetics and computational biology with particular strengths in epigenetics and chromatin structure.
The world’s first global cloud-based, full-service branding, marketing and digital agency, UP has long supported Cambridge companies but opening our office here physically puts us closer to the innovation and the people driving it. That access means we can deliver even more impact for life science leaders looking to scale globally.
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.. . The ValiRx management team comprises a mix of entrepreneurial scientists who are founders of a number of medical life sciences companies and industry-specific personnel, all with extensive experience in transferring technologies and products into the commercial arena to generate revenue and growth of shareholder value.
Watch our Member Showcase Video https://bit.ly/3fB4WZq
Watch our Member Showcase Video https://bit.ly/3fB4WZq
No data available
VasoDynamics is a Stevenage and London based, clinical-stage pharmaceutical development company. We are solely focused on developing patient-friendly, cost-effective medicines to prevent the severe side-effects induced by anticancer therapies. Our programmes are designed to prevent the common complications of cancer therapy, including mouth ulceration, dermatitis, and (permanent) hair-loss. Our philosophy is to generate affordable medicines that enable cancer patients to tolerate widely used anticancer therapies, with the dual purpose of enhancing the efficacy of anti-cancer therapy and improving patients’ quality of life with cancer, without painful, traumatic or debilitating side-effects.
VCLS (Voisin Consulting Life Sciences) is a specialist life sciences product development partner helping biotech, pharmaceutical, and medical device innovators advance complex products through regulated development and toward patient access.
With expertise across regulatory strategy, clinical research, vigilance, real-world evidence, market access, and medical, scientific, and commercial communications, VCLS supports clients from early development planning through global submissions, market access, and lifecycle management.
Our teams bring scientific depth, regulatory experience, and practical development insight to some of the most demanding areas of innovation, including orphan and rare diseases, advanced therapies, biologics, combination products, and medical devices.
Founded in 1997, VCLS works with emerging and established life sciences companies worldwide to help navigate complex development decisions, transform data into evidence, support evidence and value generation, and advance innovation toward patient access.
With expertise across regulatory strategy, clinical research, vigilance, real-world evidence, market access, and medical, scientific, and commercial communications, VCLS supports clients from early development planning through global submissions, market access, and lifecycle management.
Our teams bring scientific depth, regulatory experience, and practical development insight to some of the most demanding areas of innovation, including orphan and rare diseases, advanced therapies, biologics, combination products, and medical devices.
Founded in 1997, VCLS works with emerging and established life sciences companies worldwide to help navigate complex development decisions, transform data into evidence, support evidence and value generation, and advance innovation toward patient access.
No data available